…
MustGrow Biologics Corp., an agricultural biotechnology company, focuses on development and commercialization of natural biological technologies and products from mustard plants. The company provides Biocontrol technology platform to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and others; treat unwanted plant growth for use in organic agriculture, and home and garden markets, as well as agriculture markets where glyphosate has been banned; and suppress sprouting, and treat disease and pathogen for storage and food preservation markets. It also offers TerraMG, a mustard-derived soil biopesticide technology. In addition, the company is developing TerraSante, an organic soil amendment and biofertility technology. Further, it sells biostimulants, micronutrients, nitrogen stabilizers, and foliars. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
MustGrow Biologics Corp. develops biological crop inputs to reduce reliance on conventional agrochemicals. Growth drivers include rising demand for sustainable inputs, regulatory pressure on some pesticides, and advancement of its development-to-commercialization pipeline that may benefit from broader adoption. Investors may find the company attractive as it targets lower-residue agriculture.
Key risks are limited operating history and revenues, dependence on successful field results and regulatory approvals, competition from large agrochemical firms and other biologicals makers, and execution and financing risk to scale production and distribution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -4.89M | -0.68M | -5.57M | -3.06M | -3.31M |
| Net income | -4.89M | -0.68M | -5.57M | -3.06M | -3.31M |
| Selling general administrative | 3.82M | 3.68M | 4.48M | 2.08M | 2.86M |
| Gross profit | 0.30M | 4.71M | - | - | - |
| Operating income | -5.11M | -0.80M | -5.69M | -3.01M | -3.37M |
| Interest expense | - | 0.00M | 0.01M | 0.05M | 0.05M |
| Interest income | 0.20M | 0.21M | 0.10M | 0.00M | - |
| Net interest income | 0.20M | 0.21M | 0.09M | -0.05M | -0.05M |
| Total revenue | 0.40M | 4.71M | 0.01M | 0.01M | 0.00M |
| Total operating expenses | 5.51M | 5.52M | 5.69M | 3.03M | 3.37M |
| Cost of revenue | 0.10M | 0.00M | - | - | - |
| Total other income expense net | 0.02M | -0.08M | 0.03M | -0.00M | 0.11M |
| Net income from continuing ops | -4.89M | -0.68M | -5.57M | -3.06M | -3.31M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 5.42M | 6.94M | 7.13M | 9.70M | 3.37M |
| Total liab | 3.25M | 1.35M | 1.90M | 1.25M | 1.05M |
| Total stockholder equity | 2.17M | 5.58M | 5.24M | 8.46M | 2.32M |
| Capital stock | 25.33M | 25.06M | 24.03M | 23.03M | 14.14M |
| Retained earnings | -28.17M | -23.28M | -22.60M | -17.04M | -13.97M |
| Cash | 3.00M | 6.82M | 7.02M | 9.62M | 3.31M |
| Total current liabilities | 2.90M | 1.21M | 1.54M | 0.86M | 0.35M |
| Short long term debt | 0.39M | 0.62M | 0.40M | 0.37M | 0.21M |
| Total current assets | 4.66M | 6.94M | 7.13M | 9.70M | 3.37M |
| Long term debt | 0.12M | 0.14M | 0.36M | 0.38M | 0.70M |
| Inventory | 1.43M | - | - | - | - |
| Accounts payable | - | - | - | - | 0.14M |
| Non current assets total | 0.76M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Net borrowings | -0.24M | - | - | - | - |
| Total cash from financing activities | -0.24M | 0.10M | 0.65M | 8.72M | 1.86M |
| Net income | -4.89M | -0.68M | -5.57M | -3.06M | -3.31M |
| Change in cash | -3.82M | -0.20M | -2.60M | 6.31M | -0.72M |
| Begin period cash flow | 6.82M | 7.02M | 9.62M | 3.31M | 4.03M |
| End period cash flow | 3.00M | 6.82M | 7.02M | 9.62M | 3.31M |
| Total cash from operating activities | -3.58M | -0.29M | -3.26M | -2.41M | -2.58M |
| Issuance of capital stock | - | - | 0.00M | 6.59M | 0.00M |
| Change to inventory | -0.30M | - | - | - | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.11M | -0.54M | 0.60M | 0.33M | 0.01M |
| Stock based compensation | 1.47M | 0.93M | 1.69M | 0.27M | 0.78M |
| Other non cash items | -0.27M | - | 0.01M | 0.05M | 0.05M |
| Free cash flow | -3.58M | -0.29M | -3.26M | -2.41M | -2.58M |
Sector: Basic Materials Industry: Agricultural Inputs
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MGRO MustGrow Biologics Corp. |
-0.02 4.88% |
0.39 | - | - | 4.59 | 12.32 | 4.39 | -10.12 |
| IFOS Itafos Corp |
0.14 7.11% |
2.11 | 4.38 | 7.72 | 1.24 | 1.14 | 0.96 | 2.79 |
MustGrow Biologics Corp., an agricultural biotechnology company, focuses on development and commercialization of natural biological technologies and products from mustard plants. The company provides Biocontrol technology platform to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and others; treat unwanted plant growth for use in organic agriculture, and home and garden markets, as well as agriculture markets where glyphosate has been banned; and suppress sprouting, and treat disease and pathogen for storage and food preservation markets. It also offers TerraMG, a mustard-derived soil biopesticide technology. In addition, the company is developing TerraSante, an organic soil amendment and biofertility technology. Further, it sells biostimulants, micronutrients, nitrogen stabilizers, and foliars. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Corey J. Giasson B.Sc., MBA | Pres, CEO & Director | 1978 |
| Mr. Todd L. Lahti CA, CFA | CFO & Corp. Sec. | 1966 |
| Mr. Colin Bletsky | COO & Director | NA |
| Mr. Corey J. Giasson B.Sc., MBA | President, CEO & Director | 1978 |
| Mr. Todd L. Lahti CA, CFA | CFO & Corporate Secretary | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.